#United States #Carlsbad #Protillion Biosciences #Robert Hollingsworth #CollectiveMinds

CollectiveMinds LLC Appoints Dr. Robert Hollingsworth as Chief Scientific Officer of Protillion Biosciences

HERNDON, Va., March 31, 2026 /PRNewswire/ -- The innovative executive search firm, CollectiveMinds LLC, has announced a significant leadership appointment. Robert Hollingsworth, PhD, known for his extensive experience in the biotechnology and pharmaceutical industries, is now the Chief Scientific Officer (CSO) of Protillion Biosciences, Inc. This appointment is set to bolster Protillion's capabilities in antibody discovery and development.

Protillion Biosciences, a venture-funded biotechnology company based in Carlsbad, California, focuses on pioneering advancements in therapeutic antibodies. The support from ARCH Venture Partners and Illumina Ventures underscores the company’s commitment to groundbreaking development in the field. CollectiveMinds facilitated this vital appointment as part of their mission to provide exceptional leadership to life sciences organizations.

Dr. Hollingsworth brings over 30 years of expertise to this new role. His previous positions include Chief Scientific Officer at Shoreline Therapeutics and leadership roles within Pfizer, where he significantly contributed to the development of cancer vaccines and immunotherapeutics. His career trajectory showcases a commitment to scientific excellence, with an educational background that includes a PhD from the University of Colorado and a postdoctoral fellowship recognized by the American Cancer Society.

Tara Kochis, Founder of CollectiveMinds LLC, praised Dr. Hollingsworth’s unique ability to inspire teams while driving scientific innovation forward. “Bob’s impressive history of transforming novel scientific backgrounds into impactful clinical assets speaks volumes about his capabilities. At this pivotal time for Protillion, we believe he is the ideal CSO who can inspire teams and further their mission,” said Kochis.

Curtis Layton, CEO of Protillion Biosciences, echoed this sentiment, expressing confidence in Dr. Hollingsworth’s skills to bridge the gap between scientific innovation and practical applications. “Bob not only possesses a wealth of knowledge in translating discoveries into viable medicines, but he also exemplifies a commitment to pushing the boundaries of research and development,” stated Layton. His leadership is expected to significantly propel Protillion’s ambitious goals in redefining antibody discovery processes.

The core of Protillion’s innovative approach lies within its proprietary Prot-MaP™ on-chip antibody discovery platform. This cutting-edge technology allows for unmatched speed and precision in engineerings novel biologics, creating vast quantitative antibody binding datasets. This methodology creates fertile ground for AI-driven optimization of therapeutic antibodies, setting Protillion apart in the competitive biotech landscape.

CollectiveMinds LLC’s initiative to enhance leadership within the biotech community reflects the growing importance of strategic recruitment in achieving corporate ambitions. Their commitment to excellence ensures that companies like Protillion Biosciences can attract the best talent, driving innovation and developmental success.

For further details on CollectiveMinds LLC, visit their website: www.collectivemindsllc.com or reach them directly via email at [email protected].

About Protillion Biosciences

Protillion Biosciences is at the forefront of next-generation therapeutic antibody discovery. With a foundational focus on innovative biotechnology, the company remains dedicated to rapidly translating its revolutionary findings into effective treatments, thanks to a powerful backer network and their uniquely devised technology. Their commitment to examining and transforming the landscape of antibody development positions them as a leader in the biotechnology field.